Prostate cancer and endocrine treatment
Clinical research at Deventer Ziekenhuis includes men with prostate cancer receiving abiraterone, with attention to treatment-related effects relevant to oncology care.
- Androgen deprivation
- Hormone-sensitive prostate cancer
- Urologic oncology
The sponsor’s research interest centers on the medical management of prostate cancer in the setting of androgen-targeted therapy.
Pharmacology and drug metabolism
The funded study examines how abiraterone influences drug metabolism in patients, reflecting a focus on clinically important pharmacological interactions.
- Pharmacokinetics
- Drug-drug interactions
- Metabolic pathways
This area is relevant to the safe use of concomitant medicines in patients treated for oncology-related conditions.
Pain management in cancer care
Research activity also addresses the use of oxycodone in men with prostate cancer, linking symptom control with treatment-related medication effects.
- Opioid analgesia
- Cancer-related pain
- Analgesic response
The clinical interest lies in optimizing pain treatment alongside ongoing cancer therapy.
Clinical pharmacotherapy in hospital practice
As a hospital-based sponsor, Deventer Ziekenhuis contributes research within clinical pharmacotherapy, with emphasis on medication use in routine specialist care.
- Medication safety
- Concomitant therapy
- Specialist outpatient care
The research landscape reflects interest in how cancer therapies interact with commonly used supportive medicines in a hospital setting.
